Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283117 | 0.74 | HDAC4 (0.34) | HDAC4MEN1CYP2C9KMT2AOPRM1 | |
| SCHEMBL27449113 | 0.72 | HDAC4 (0.33) | HDAC4MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL8039521 | 0.72 | PNMT (0.39) | OPRM1 | |
| SCHEMBL5665863 | 0.71 | HDAC4 (0.32) | HDAC4OPRM1OPRK1OPRL1 | |
| SCHEMBL16163009 | 0.71 | HDAC4 (0.32) | HDAC4OPRM1OPRK1OPRL1 | |
| SCHEMBL276639 | 0.71 | HDAC4 (0.32) | HDAC4OPRM1OPRK1OPRL1 | |
| SCHEMBL3357684 | 0.71 | HDAC4 (0.36) | HDAC4OPRM1OPRK1OPRL1 | |
| SCHEMBL9629458 | 0.71 | HDAC4 (0.36) | HDAC4MEN1KMT2AOPRM1OPRK1 | |
| SCHEMBL5715764 | 0.71 | MAOB (0.38) | HDAC4OPRM1OPRK1OPRL1 | |
| SCHEMBL4089733 | 0.71 | HDAC4 (0.36) | HDAC4OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0377634-B1 | PROCESS FOR THE PREPARATION OF ARYL SULFIDES | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1992-12-02 | — | — | EP | claimed |
| US-20230000982-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING NOVEL TRIFLUOROMETHYL PHENYL PYRAZOLE DERIVATIVE AS ACTIVE INGREDIENT | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-114728909-A | Composition for preventing or treating cancer comprising novel trifluoromethylphenylpyrazole derivative as active ingredient | 韩国原子力医学院 | 2022-07-08 | — | — | CN | disclosed |
| EP-4015506-A2 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING NOVEL TRIFLUOROMETHYL PHENYL PYRAZOLE DERIVATIVE AS ACTIVE INGREDIENT | Korea Institute of Radiological & Medical Sciences (KR) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021060888-A2 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING NOVEL TRIFLUOROMETHYL PHENYL PYRAZOLE DERIVATIVE AS ACTIVE INGREDIENT | 한국원자력의학원 | 2021-04-01 | — | — | WO | disclosed |
| EP-2332931-B1 | NOVEL COMPOUND, METHOD FOR PREPARING SAME AND ORGANIC ELECTRONIC DEVICE USING SAME | LG CHEMICAL LTD (KR) | 2015-04-22 | — | — | EP | disclosed |
| US-6103743-A | Unsaturated amino acid derivatives | ALLELIX NEUROSCIENCE, INC. (US) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000982-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING NOVEL TRIFLUOROMETHYL PHENYL PYRAZOLE DERIVATIVE AS ACTIVE INGREDIENT | CASP3, API5, HDAC1 | HDAC4 38/4885MEN1 4327/4885CYP2C9 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.